Divis Laboratories Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3hb49052il3f1s6vwkoah053.pdf

Key Takeaways


The Margin Shock: What Happened and the Path Back

Dr. Murali K. Divi: "We are not talking about immediately in the next 3, 4 quarters to reach such level. But definitely, it is possible. ... I think we will see in the next 2 years, probably we should be back with such."

Volume: The Silver Lining Under the Pricing Storm

Dr. Murali K. Divi: "We cannot compare with the previous 5, 6 quarters, where we had exceptional opportunity. We used the speed, took challenges and you see the pre-COVID business, I think we are seeing normal growth in the coming quarters and profitability should improve quarter-on-quarter."

Contrast Media: The Next Growth Engine Takes Shape

Dr. Murali K. Divi: "There are not many customers who would consume the contrast media, both iodine compound, gadolinium compounds. There are only a handful in the whole world. And with the majority of them….. we are discussing for long-term agreement for supply of these APIs."

Kakinada: The Long-Dated Capacity Call Option


The Pipeline Beyond Contrast Media

Dr. Murali K. Divi: "Why not more?"

Guidance & Commitments

CommitmentSpecificsTimeline
Margin recoveryGross margins to improve; profitability to increase QoQComing quarters
EBITDA margin normalizationReturn to ~40% EBITDA levelsWithin 2 years
Contrast media commercial supplyCommercial supply for both custom synthesis project and own generics to startQ1 FY2024
Fast-track CS projects ramp-upTwo completed projects to fully ramp; some values visible through Q4Full ramp by Q1 FY2024
NCE-based molecule volumesGood volumes from NCE launchesFY2025
Kakinada Phase 1 constructionFull swing construction to beginNext 1–2 quarters
Kakinada facility readinessFacility ready to produce starting materials, intermediates, APIs2–3 years
Double-digit growthBoth sales and profitability to grow double digits, enabled by six growth enginesOngoing (no quarter specified)

Key Metrics

MetricQ3 FY23
Consolidated total revenue₹1,822 cr, vs ₹2,510 cr in Q3 FY22
Material consumption43% of sales revenue, due to change in product mix
Profit before tax₹436 cr
Effective tax rate29%
Profit after tax₹307 cr
Exports share87% of revenue
Europe and America export share69% of revenue for the quarter, 70% for 9M FY23
Generics to custom synthesis mix60% to 40% for the quarter, 55% to 45% for 9M FY23
Forex gain₹47 cr for the quarter, ₹134 cr for 9M FY23
Constant currency growthnegative 40% for the quarter, negative 17% for 9M FY23
Nutraceutical business revenue₹160 cr for the quarter, ₹509 cr for 9M FY23
Cash on books₹3,849 cr as of 31st December
Receivables₹1,659 cr as of 31st December
Inventories₹2,981 cr as of 31st December
Capital work-in-progress~₹575 cr at end of quarter
Capacity occupancy75% to 77%, implying at least 20% to 25% free capacity
API price decline range5% to 10% on some APIs
Gross margin QoQ changedown almost 7 percentage points QoQ
Custom synthesis revenue (per analyst's math)₹675 cr this quarter, vs ₹680 cr in Q3 FY21 (per an analyst's math)